Abstract
Background Autonomic dysfunction is a common complication of post-acute sequalae of SARS-CoV-2 (PASC)/long COVID, however prevalence and severity rates are unknown.
Objective The primary goal of this study was to assess the frequency and severity of autonomic symptoms in PASC. We also aimed to assess symptom burden in PASC though well-validated questionnaires, evaluate which pre-existing conditions are associated with an increased risk of developing autonomic dysfunction, and determine whether the severity of acute COVID-19 illness is associated with the severity of autonomic dysfunction in this population.
Methods We conducted an online survey of 2,314 adults with PASC using several validated questionnaires including the COMPASS-31 to evaluate for autonomic dysfunction. We included both participants who had tested positive for COVID-19 (test-confirmed) and participants who were diagnosed with COVID-19 based on clinical symptoms alone (test-unconfirmed). Additional analyses were performed on test-confirmed participants, comparing hospitalized to non-hospitalized participants.
Results 67% of PASC patients had a COMPASS-31 score >20, suggestive of moderate to severe autonomic dysfunction. COMPASS-31 scores did not differ between test-confirmed hospitalized and non-hospitalized participants (28.95±30.98 vs 26.4±28.35, p=0.06). Both hospitalized and non-hospitalized participants reported significant functional disability across all quality-of-life domains.
Conclusions Moderate to severe autonomic dysfunction was seen in all PASC groups in our study, independent of hospitalization status, suggesting that autonomic dysfunction is highly prevalent in the PASC population and not necessarily dependent on the severity of acute COVID illness.
Competing Interest Statement
Disclosures NL: Grant from Dysautonomia International; Stock or stock options in Health Care Select SPDR, Ishares Biotechnology LS: Consulting fees from Eisai Pharmaceuticals (Ad board, unrelated to current manuscript) and Jazz Pharmaceuticals (Ad board, unrelated to current manuscript); Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Jazz Pharmaceuticals, Xywav, Xyrem and Sunosi; Payment for expert testimony from City and County of San Francisco (Sleep deprivation cases); Support for attending meetings and/or travel from Jazz Pharmaceuticals (Psych Congress 2021, poster presentation); Leadership or fiduciary role in other board, society, committee or advocacy group from Graduate Education Subcommittee Chair (AAN, unpaid), Graduate Education Subcommittee Chair (AAN, unpaid), Editorial Board (Practical Neurology, Unpaid); Stock or stock options in Alphabet SM: Grants or contracts from the Myasthenia Gravis Foundation of America; Consulting fees from Argenx, Alexion and UCB pharma (consultation and advisory board meetings) MM: Royalties from Elsvier Inc.; Consulting fees from 2nd MD, Infinite MD and Guidepoint LLC; Payments for CME lectures from MED-IQ; Payment for expert testimony from Van Cott Talamante (expert witness); Medical Advisory Board of Dysautonomia International, and MSA Coalition
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Stanford University and Stony Brook University Institutional Review Boards, and all participants gave digital informed consent before starting the survey.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding support: None
Disclosures:
NL – Grant from Dysautonomia International; Stock or stock options in Health Care Select SPDR, Ishares Biotechnology
LS - Consulting fees from Eisai Pharmaceuticals (Ad board, unrelated to current manuscript) and Jazz Pharmaceuticals (Ad board, unrelated to current manuscript); Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Jazz Pharmaceuticals, Xywav, Xyrem and Sunosi; Payment for expert testimony from City and County of San Francisco (Sleep deprivation cases); Support for attending meetings and/or travel from Jazz Pharmaceuticals (Psych Congress 2021, poster presentation); Leadership or fiduciary role in other board, society, committee or advocacy group from Graduate Education Subcommittee Chair (AAN, unpaid), Graduate Education Subcommittee Chair (AAN, unpaid), Editorial Board (Practical Neurology, Unpaid); Stock or stock options in Alphabet
SM- Grants or contracts from the Myasthenia Gravis Foundation of America; Consulting fees from Argenx, Alexion and UCB pharma (consultation and advisory board meetings)
MM - Royalties from Elsvier Inc.; Consulting fees from 2nd MD, Infinite MD and Guidepoint LLC; Payments for CME lectures from MED-IQ; Payment for expert testimony from Van Cott Talamante (expert witness); Medical Advisory Board of Dysautonomia International, and MSA Coalition
Data Availability
All data produced in the present study are available upon reasonable request to the authors.